Manifestaciones neurológicas asociadas a la vacuna contra COVID-19

Manifestaciones neurológicas asociadas a la vacuna contra COVID-19

Resumen: Introducción: La enfermedad por coronavirus 2019 (COVID-19) se ha propagado de forma rápida, dando lugar a una situación de pandemia, con importante morbimortalidad. En este contexto han surgido un amplio número de vacunas para tratar de hacer frente a la enfermedad. Objetivo: Revisar los...

Full description

Saved in:

Bibliographic Details
Main Authors:	R. Alonso Castillo, J.C. Martínez Castrillo
Format:	Article
Language:	Spanish
Published:	Elsevier España 2025-01-01
Series:	Neurología
Subjects:	COVID-19 vaccines SARS-CoV-2 vaccines Adverse event Neurological manifestations Neurological pathology Safety
Online Access:	http://www.sciencedirect.com/science/article/pii/S0213485322001876
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals
by: Najwa D. Aljehani, et al.
Published: (2025-01-01)

Vaccination caused an underestimation of the cumulative incidence of SARS-CoV-2 infection
by: Nana Owusu-Boaitey
Published: (2025-02-01)

Acute cerebral edema: a lethal neurological complication in a patient with COVID-19 infection. Case report and literature review
by: M. Puodžiūnaitė, et al.
Published: (2023-10-01)

Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
by: Guiqiang Wang, et al.
Published: (2025-12-01)

COVID-19 vaccination: challenges in the pediatric population
by: Alice Nicoleta Azoicai, et al.
Published: (2025-01-01)

Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
by: Fengcai Zhu, et al.
Published: (2025-01-01)

COVID-19 Vaccine Hesitancy Among Various Segments of the Population in Turkey: A Literature Review
by: Sezer Okay
Published: (2025-01-01)

Estimating the Effectiveness of Pfizer and Sinopharm Vaccines and their Relationship to Occupation, Residence, Smoking, and Body Mass Index During Pregnancy Smoking
by: Shahad Th. Jameel, et al.
Published: (2025-01-01)

Neurological side effects of SARS-CoV-2 vaccination are common and can be severe
by: Josef Finsterer
Published: (2025-02-01)

Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine
by: Dandan Peng, et al.
Published: (2023-04-01)

Impaired Hepatitis B and COVID-19 vaccination responses show strong concordance in hemodialysis patients with end stage renal disease
by: Karsten Lürken, et al.
Published: (2025-01-01)

Reply to “Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection”
by: Jefferson M. Jones, et al.
Published: (2025-02-01)

Serological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand
by: Daniel Ward, et al.
Published: (2025-01-01)

Mucosal Immunization with an Influenza Vector Carrying SARS-CoV-2 N Protein Protects Naïve Mice and Prevents Disease Enhancement in Seropositive Th2-Prone Mice
by: Mariia V. Sergeeva, et al.
Published: (2024-12-01)

Adjuvanted subunit intranasal vaccine reduces SARS-CoV-2 onward transmission in hamsters
by: Yongjun Sui, et al.
Published: (2025-02-01)

Dengue fever presenting with cerebellitis: A case report
by: Santhirasekaram Sathees, et al.
Published: (2025-01-01)

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialResearch in context
by: Gabriela Tapia-Calle, et al.
Published: (2025-01-01)

Impact of Metabolic States on SARS-CoV-2 Vaccine Responses in Mouse Models of Obesity and Diabetes
by: Olivia A. Smith, et al.
Published: (2024-12-01)

Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms
by: Mie Suzuki Okutani, et al.
Published: (2025-02-01)

Mechanism of modified mRNA structure in COVID-19 vaccines for inducing neutralizing antibodies
by: Sabighoh Zanjabila, et al.
Published: (2024-10-01)

Next generation sequencing of multiple SARS-CoV-2 infections in the Omicron Era
by: Marzia Cavalli, et al.
Published: (2025-01-01)

Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT Study
by: R. Kaladytė Lokominienė, et al.
Published: (2024-02-01)

Long-term effects of SARS-CoV-2 infection and vaccination in a population-based pediatric cohort
by: Jakob Höppner, et al.
Published: (2025-01-01)

Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing
by: Chin Shern Lau, et al.
Published: (2024-12-01)

Distinct Neutralising and Complement-Fixing Antibody Responses Can Be Induced to the Same Antigen in Haemodialysis Patients After Immunisation with Different Vaccine Platforms
by: Nadezhda Wall, et al.
Published: (2024-12-01)

Humoral immune response after anti-SARS-CoV-2 vaccine “booster” dose in patients with monoclonal gammopathy of undetermined significance (MGUS)
by: NICOLA SGHERZA, et al.
Published: (2023-01-01)

Comparison of clinical variables and outcome of 2 natural equine herpesvirus myeloencephalopathy outbreaks induced by equine herpesvirus‐1 A2254/N752 strain in sport horses
by: María de laCuesta‐Torrado, et al.
Published: (2025-01-01)

Neurological post-COVID syndrome is associated with substantial impairment of verbal short-term and working memory
by: Jeyanthan Charles James, et al.
Published: (2025-01-01)

Case report: Development of anxiety symptoms after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine: a case series
by: Maris Taube, et al.
Published: (2025-01-01)

Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster dosesResearch in context
by: Annalisa Ciabattini, et al.
Published: (2025-03-01)

Respiratory Virus Vaccines: Pathways to Recommendations and Enhanced Coverage for At-Risk Populations
by: Stefania Maggi, et al.
Published: (2024-12-01)

Early COVID-19 and protection from Omicron in a highly vaccinated population in Ontario, Canada: a matched prospective cohort study
by: Altynay Shigayeva, et al.
Published: (2025-02-01)

Unveiling unique effector function-related bulk antibody profiles in long-term hemodialysis patients following COVID-19 mRNA booster vaccination
by: Chia-Yi Chou, et al.
Published: (2025-02-01)

Key insights into recent advances and challenges in COVID-19 management
by: Prakash Monika, et al.
Published: (2025-01-01)

An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants
by: Fábio Mambelli, et al.
Published: (2025-01-01)

SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development
by: Fabrizio Angius, et al.
Published: (2024-12-01)

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
by: Yichuan Yao, et al.
Published: (2025-01-01)

Micro and macropolitical determinants for non-vaccination against COVID-19 in pregnant women in Belo Horizonte
by: Marina Stuart Marques, et al.
Published: (2025-01-01)

Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024
by: Yamin Shu, et al.
Published: (2025-02-01)

Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O)
by: Pia Gattinger, et al.
Published: (2025-01-01)